All Oncology News

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

The Nobel Prize winning director of the National Cancer Institute, Harold Varmus, MD, has tendered his resignation to pursue research interests in New York.

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

Emmanuel S. Antonarakis, MBBCh, discusses research examining AR-V7 as a biomarker for chemotherapy efficacy in advanced prostate cancer.

OncLive and Indiana University Melvin and Bren Simon Cancer Center have joined forces to share news about the center's research and education programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.

Carfilzomib doubled progression-free survival versus bortezomib in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

The FDA has accepted a supplemental Biologics License Application for ipilimumab for the adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

GlaxoSmithKline (GSK) and Novartis have announced that a multi-billion-dollar, 3-pronged deal to exchange and share various operations has been completed.

The FDA has granted a priority review to nivolumab for use in patients with previously treated, advanced, squamous non–small cell lung cancer.

New checkpoint blockade agents that target the PD-1 pathway are moving forward quickly in the melanoma treatment paradigm and likely will become a frontline immunotherapy choice for patients with advanced or metastatic disease, according to Jason J. Luke, MD, FACP, a leading researcher in the field.

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

Treatment with eribulin mesylate significantly extended overall survival compared with dacarbazine in patients with advanced soft tissue sarcoma.

For additional insight on new agents and other emerging CLL therapies, OncLive spoke with Thomas Kipps, MD, PhD, professor of Medicine in the Division of Hematology-Oncology, and Deputy Director for Research at the UC San Diego Moores Cancer Center.

OncLive today welcomes the Medical University of South Carolina's Hollings Cancer Center as a partner in promoting the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.

In an interview with OncLive, Suzanne L. Topalian, MD, director of the Melanoma Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discussed the rapid advance of nivolumab and potential next-steps.

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.

The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.

A joint program at the NYU Langone Medical Center and the Technion-Israel Institute of Technology is positioned to attract additional, world-class support from institutions and individuals who are dedicated to eradicating cancer through focused and efficient research.

The FDA has approved panobinostat in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma, based on findings from the PANORAMA-1 trial.

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

The FDA has approved its first-ever direct-to-consumer genetic test for the detection of a gene variant that could be associated with Bloom syndrome, a rare inherited disorder associated with a higher risk of developing cancer and other health concerns.

Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.

Ibrutinib (Imbruvica) showed promising activity in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia after allogeneic stem cell transplantation, according to data presented at the American Society for Blood and Marrow Transplantation 2015 BMT Tandem Meeting.

Are the high costs of breakthrough therapies for blood cancers, some with price tags of more than $100,000 per year, worth the improved outcomes for patients?

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

Talk with almost any cancer survivor, and she/he is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory.

The oral multikinase inhibitor motesanib failed to meet the primary endpoint of improving progression-free survival in patients with non–small cell lung cancer in the phase III MONET-A trial.

OncLive and Tulane Cancer Center at the Tulane University School of Medicine have joined forces to promote awareness of new developments in cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced today.

The risk of developing the two most common types of ovarian cancer significantly increases when taking hormone replacement therapy to alleviate symptoms of menopause, according to a meta-analysis of epidemiological studies.